Larvol Delta - Exelixis-Announces-Initial-DoseEscalation-Results-from-the-FirstinHuman-Phase-1-Trial-Evaluating-XL102-in-Patients-with-Advanced-Solid-Tumors-at-SABCS-2022

XL102 - Exelixis

https://www.businesswire.com/news/home/20221207005626/en/Exelixis-Announces-Initial-Dose-Escalation-Results-from-the-First-in-Human-Phase-1-Trial-Evaluating-XL102-in-Patients-with-Advanced-Solid-Tumors-at-SABCS-2022

Dec 8, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next